Renal denervation offers a potentially transformative and minimally invasive option for treating hypertension. With this ...
Albany, NY (WRGB) — Albany Medical Center is now offering a new procedure aimed at helping patients with resistant ...
Boston Scientific is diving into the field of renal denervation, with a $540 million deal for SoniVie and its ...
Boston Scientific (NYSE: BSX) announced today that it agreed to acquire intravascular ultrasound system developer SoniVie.
The United States Food and Drug Administration, in 2023, approved renal denervation—a catheter-based procedure that ablates the renal sympathetic nerves—as an adjunctive treatment for patients ...
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech ...
Pulnovo Medical announced yesterday that it closed a Series C funding round worth proceeds of nearly $100 million.
More research is needed on alcohol-mediated perivascular renal sympathetic denervation for treating resistant hypertension before it can be used in the NHS.
GlobalData on MSN11 天
Boston Scientific buys Tivus system developer SoniVie in $540m dealThe move aims to broaden interventional cardiology therapies with ultrasound-based renal denervation therapy to treat ...
Boston Scientific Corp. agreed to acquire Sonivie Ltd., developer of a therapeutic intravascular ultrasound system for denervation to treat resistant hypertension, pulmonary hypertension and chronic ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果